Loading stock data…
$2.65-0.10 (-3.47%)
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States.
Lexeo Therapeutics, Inc. in the Healthcare sector is trading at $2.65 with a market capitalization of $217M. Wall Street consensus targets $20.30 (10 analysts), implying a +667.5% move over the next 12 months. The stock is currently near its 52-week low of $2.57, remaining 52.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 30 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$28.02M↓ | -$22.33M↑ | -$23.12M↓ | -$21.65M↑ | -$30.69M |
| Net Income | -$25.87M↓ | -$20.20M↑ | -$20.92M↓ | -$20.28M↑ | -$26.10M |
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in ph...